AR037061A1 - Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos - Google Patents
Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentosInfo
- Publication number
- AR037061A1 AR037061A1 ARP980102380A ARP980102380A AR037061A1 AR 037061 A1 AR037061 A1 AR 037061A1 AR P980102380 A ARP980102380 A AR P980102380A AR P980102380 A ARP980102380 A AR P980102380A AR 037061 A1 AR037061 A1 AR 037061A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- aralkyl
- aryl
- aminoalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- -1 cycloalkylalkylene Chemical group 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 10
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000001769 aryl amino group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001145 hydrido group Chemical group *[H] 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000006319 alkynyl amino group Chemical group 0.000 abstract 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 2
- 125000005128 aryl amino alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000004678 hydrides Chemical group 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- RXBMEHOLQJITJI-LEOXJPRUSA-N (4s)-5-amino-4-[[(2s)-2-[[(2s)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-(3-phenyl-1,2-oxazol-5-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N)CP(O)(=O)C=1C=CC(Br)=CC=1)C(ON=1)=CC=1C1=CC=CC=C1 RXBMEHOLQJITJI-LEOXJPRUSA-N 0.000 abstract 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 abstract 1
- 125000006323 alkenyl amino group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 abstract 1
- 125000005122 aminoalkylamino group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000005352 carboxycycloalkyl group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000004992 haloalkylamino group Chemical group 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 abstract 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto derivado de pirazol sustituido, caracterizado por tener la fórmula (1), donde: R1 se selecciona entre hidrido, alquilo, cicloalquilo, alquenilo, alquinilo, cicloalquilalquileno, haloalquilo, hidroxialquilo, alcoxialquilo, mercaptoalquilo, alquiltioalquileno, amino, aminoalquilo, alquilamino, arilamino, alquilaminoalquileno, y heterociclilalquileno; o R1 tiene la fórmula (2) donde: i es un entero entre 0 y 9; R25 se selecciona entre hidrógeno, alquilo aralquilo, heterociclilalquilo, alcoxialquileno, ariloxialquileno, aminoalquilo, alquilaminoalquilo, arilaminoalquilo, alquilcarbonilalquileno, arilcarbonilalquileno, y heterociclilcarbonilaminoalquileno; y R26 se selecciona entre hidrógeno, alquilo, alquenilo, alquinilo, cicloalquilalquileno, aralquilo, alcoxicarbonilalquileno, y alquilaminoalquilo; y R27 se selecciona entre alquilo, cicloalquilo, alquinilo, arilo, heterociclilo, aralquilo, cicloalquilalquileno, cicloalquenilalquileno, cicloalquilarileno, cicloalquilcicloalquilo, heterociclilalquileno, alquilarileno, alquilaralquilo, aralquilarileno, alquilheterociclilo, alquilheterociclilalquileno, alquilheterociclilarileno, aralquilheterociclilo, alcoxialquileno, alcoxiarileno, alcoxiaralquilo, alcoxiheterociclilo, alcoxialcoxiarileno, ariloxiarileno, aralcoxiarileno, alcoxiheterociclilalquileno, ariloxialcoxiarileno, alcoxicarbonilalquileno, alcoxicarbonilheterociclilo, alcoxicarbonilheterociclilcabonialquileno, aminoalquilo, alquilaminoalquileno, arilaminocarbonilalquileno, alcoxiarilaminocarbonilalquileno, aminocarbonilalquileno, arilaminocarbonilalquileno, alquilaminocarbonilalquileno, arilcarbonilalquileno, alcoxicarbonilarileno, ariloxicarbonilarileno, alquilariloxicarbonilarileno, arilcarbonilarileno, alquilarilcarbonilarileno, alcoxicarbonilheterociclilarileno, alcoxicarbonilalcoxilarileno, heterociclilcarbonilalquilarileno, alquitioalquileno, cicloalquitioalquileno, alquitioarileno, aralquiltioarileno, heterocicliltioarileno,ariltioalquilarileno, arilsulfonilaminoalquileno, alquilsulfonilareno, alquilaminosulfonilarileno; donde dichos grupos alquilo, cicloalquilo, arilo, heterociclilo, aralquilo, heterociclilalquileno, alquiheterociclilarileno, alcoxiarileno, ariloxiarileno, arilaminocarbonilalquileno, ariloxicarbonilarileno, arilcarbonilarileno, alquitioarileno, heterocicliltioarileno, ariltioalquilarileno, y alquisulfonilarileno están opcionalmente sustituidos con uno o más radicales seleccionados independientemente entre alquilo, halo, haloalquilo, alcoxi, ceto, amino, nitro, y ciano; o R27 es -CHR28R29 donde R28 es alcoxicarbonilo, y R29 se selecciona entre aralquilo, aralcoxialquileno, heterociclilalquileno, alquilheterociclilalquileno, alcoxicarbonilalquileno, alquiltioalquileno, y aralquitioalquileno; donde dichos grupos aralquilo y heterociclilo grupos están opcionalmente sustituidos con uno o más radicales seleccionados independientemente entre alquilo y nitro; o R26 y R27 junto con el átomo de nitrógeno al cual se encuentran unidos forman un heterociclo, donde dicho heterociclo está opcionalmente sustituido con uno o más radicales seleccionados independientemente entre alquilo, arilo, heterociclilo, heterociclilalquileno, alquilheterociclilalquileno, ariloxialquileno, alcoxiarileno, alquilariloxialquileno, alquilcarbonilo, alcoxicarbonilo, aralcoxicarbonilo, alquilamino, alcoxicarbonilamino; donde dichos radicales arilo, heterociclilalquileno y ariloxialquileno están opcionalmente sustituidos con uno o más radicales seleccionados independientemente entre halógeno, alquilo y alcoxi; y R2 se selecciona entre hidrido, halógeno, alquilo, arilo, haloalquilo, hidroxialquilo, heterociclilo, alquilheterociclilo, heterociclilalquilo, alquilamino, alquinilamino, arilamino, heterociclilamino, heterociclilalquilamino, aralquilamino, aminoalquilo, aminoalquilamino, alquilaminoalquilamino, cicloalquilo, alquenilo, cicloalquenilo, alcoxi, alquiltio, carboxi, carboxialquilamino, alcoxicarbonilo, carboxialquilo, carboxicicloalquilo, heterociclilcarbonilo, alcoxicarbonilheterociclilo, alcoxicarbonilheterociclilcarbonilo, alcoxicarbonilalquilo, alcoxialquilamino, y alcoxicarbonilaminoalquilamino; donde los grupos arilo, heterociclilo, heterociclilalquilo, cicloalquilo y cicloalquenilo están opcionalmente sustituidos con uno o más radicales seleccionados independientemente entre halo, ceto, alquilo, arilo, aralquilo, heterociclilo, heterociclilalquilo, carboxi, alcoxi, ariloxi, aralcoxi, haloalquilo, alquilamino, alquilaminoalquilamino, alquinilamino, heterociclilalquilamino, alquilcarbonilo, alcoxicarbonilo, alquilsulfonilo, aralquilsulfonilo, y arilsulfonilo; o R2 tiene la fórmula (3) donde: j es un entero entre 0 y 8; y m es 0 ó 1; y R30 y R31 son seleccionados independientemente entre hidrógeno, alquilo, arilo, heterociclilo, aralquilo, heterociclilalquileno, aminoalquilo, alquilaminoalquilo, aminocarbonilalquilo, alcoxialquilo, y alquilcarboniloxialquilo; y R32 se selecciona entre hidrógeno, alquilo, aralquilo, heterociclilalquilo, alcoxialquileno, ariloxialquileno, aminoalquilo, alquilaminoalquilo, arilaminoalquilo, alquilcarbonilalquileno, arilcarbonilalquileno, y heterociclilcarbonilaminoalquileno; R33 se selecciona entre hidrógeno, alquilo, -C(O)R35, -C(O)OR35, SO2R36, -C(O)NR37R38, y -SO2NR39R40, donde R35, R36; R37, R38, R39 y R40 son independientemente seleccionados entre hidrocarburo, hidrocarburo heterosubstituido y heterociclilo; y R34 se selecciona entre hidrógeno, alquilo, aminocarbonilo, alquilaminocarbonilo, y arilaminocarbonilo; o R2 es -CR41R42 donde R41 es arilo, y R42 es hidroxi; y R3 se selecciona entre piridinilo, pirimidinilo, quinolinilo, purinilo, o es un resto seleccionado del grupo de fórmula (4), donde R43 se seleccionan entre hidrógeno, alquilo, aminoalquilo, alcoxialquilo, alquenoxialquilo, y ariloxialquilo; y donde los grupos R3 piridinilo, pirimidinilo, quinolinilo y purinilo son opcionalmente sustituidos con uno o más radicales independientemente seleccionados entre halo, alquilo, aralquilo, aralquenilo, arilheterociclilo, carboxi, alcoxi, alquiltio, alquilsulfinilo, alquilsulfonilo, aralcoxi, amino, cicloalquilamino, aminocarbonilo, ciano, hidroxi, alcoxicarbonilo, alcoxicarbonilamino, alcoxiaralquilamino,. aminosulfonilo, alquilamino, alquenilamino, alquinilamino, alquilaminoalquilamino, hidroxialquilamino, heterociclilamino, heterociclilalquilamino, aralquilheterociclilamino, nitro, arilamino, aralquilamino, alquilaminocarbonilo, alquilcarbonilamino, halosulfonilo, aminoalquilo, haloalquilo, alquilcarbonilo, alcoxiaralquilamino, hidrazinilo, alquihidrazinilo, o -NR44R45 donde R44 es alquilcarbonilo o amino, y R45 es alquilo o aralquilo, y R4 se selecciona entre hidrido, cicloalquilo, cicloalquenilo, arilo, y heterociclilo, donde R4 es opcionalmente sustituido con uno o más radicales seleccionados independientemente entre alquiltio, alquilsulfonilo, alquilsulfinilo, halo, alquilo, alquinilo, alcoxi, ariloxi, aminocarbonilo, alquilaminocarbonilo, alcoxicarbonilo, heterociclilo, haloalquilo, amino, ciano, nitro, alquilamino, e hidroxi; con la condición de que R3 no es 2-piridinilo cuando R4 es un anillo fenilo que contiene un sustituyente 2-hidroxi y cuando R1 es hidrido; y también con la condición de que R2 es seleccionado entre arilo, heterociclilo, cicloalquilo y cicloalquenilo insustituido cuando R4 es hidrido; y además con la condición de que R4 no es metilsulfonilfenilo; o una sal aceptable para uso farmacéutico o tautómero del mismo. Se presenta también una composición farmacéutica que contiene dicho compuesto y el uso de dicho compuesto en la preparación de medicamentos útiles para tratar afecciones mediadas por TNF, por p38 quinasa, y para tratar la artritis y la inflamación. También se describe un proceso para la preparación de dicho compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4753597P | 1997-05-22 | 1997-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037061A1 true AR037061A1 (es) | 2004-10-20 |
Family
ID=21949533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102380A AR037061A1 (es) | 1997-05-22 | 1998-05-22 | Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos |
Country Status (14)
Country | Link |
---|---|
US (1) | US5932576A (es) |
EP (1) | EP0983260A2 (es) |
JP (1) | JP2002502379A (es) |
KR (1) | KR20010012808A (es) |
CN (1) | CN1264376A (es) |
AR (1) | AR037061A1 (es) |
AU (1) | AU755498B2 (es) |
BR (1) | BR9809451A (es) |
CA (1) | CA2288741A1 (es) |
IL (1) | IL132736A0 (es) |
NO (1) | NO995635L (es) |
PL (1) | PL336990A1 (es) |
RU (1) | RU2249591C2 (es) |
WO (1) | WO1998052937A2 (es) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
EP1023066A4 (en) | 1997-06-13 | 2001-05-23 | Smithkline Beecham Corp | NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
IL136738A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
MY132496A (en) * | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
AU4994899A (en) * | 1998-07-13 | 2000-02-01 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
WO2000019824A1 (en) | 1998-10-07 | 2000-04-13 | Smithkline Beecham Corporation | Novel treatment for stroke management |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
DE69903976T2 (de) | 1998-12-16 | 2003-07-24 | Aventis Pharma Ltd | Heteroaryl-zyklische acetale |
CA2356263C (en) * | 1998-12-25 | 2009-04-21 | Teikoku Hormone Mfg. Co., Ltd. | Aminopyrazole derivatives |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
JP2000281588A (ja) * | 1999-03-30 | 2000-10-10 | Sankyo Co Ltd | ガンの予防又は治療薬及びそのスクリーニング方法 |
US7122666B2 (en) * | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1235814B1 (en) | 1999-11-23 | 2004-11-03 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
WO2001056557A2 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
WO2003018008A1 (fr) * | 2000-02-25 | 2003-03-06 | Shionogi & Co., Ltd. | Agent d'accélération de l'expression de apo ai |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
ES2237671T3 (es) * | 2001-02-02 | 2005-08-01 | Smithkline Beecham Corporation | Derivados de pirazol contra la sobreexpresion de tgf. |
ES2271322T3 (es) * | 2001-04-13 | 2007-04-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun y otras proteinas quinasa. |
ES2310202T3 (es) | 2001-04-26 | 2009-01-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo. |
GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
CN1547486A (zh) | 2001-06-26 | 2004-11-17 | 抗opgl抗体 | |
JP4342939B2 (ja) * | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
KR100697482B1 (ko) | 2001-09-25 | 2007-03-20 | 파마시아 코포레이션 | 치환된 피라졸의 제조 방법 |
US7057049B2 (en) | 2001-09-25 | 2006-06-06 | Pharmacia Corporation | Process for making substituted pyrazoles |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
DE10294485T5 (de) * | 2001-10-29 | 2004-04-29 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind |
ATE374753T1 (de) * | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
NZ533865A (en) * | 2002-02-12 | 2006-02-24 | Smithkline Beecham Corp | Nicotinamide derivates useful as p38 inhibitors |
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
US20050124620A1 (en) * | 2002-04-09 | 2005-06-09 | Martyn Frederickson | Pharmaceutical compounds |
AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
EP1504004B1 (en) | 2002-05-10 | 2007-06-27 | SmithKline Beecham Corporation | Substituted pyrazolopyrimidines |
CA2492033A1 (en) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
CA2497007A1 (en) | 2002-09-09 | 2004-03-18 | Amgen Inc. | 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations |
AP2005003263A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Pyrazole derivatives as transforming growth factor(TGF) inhibitors. |
AU2003263431A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
JP4518956B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子(tgf)阻害剤としての新規トリアゾールおよびオキサゾール化合物 |
AP2005003260A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel triazole compounds as transforming growth factor (TGF) inhibitors. |
MXPA05002981A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf). |
AU2003266617B2 (en) | 2002-09-25 | 2009-01-29 | Ube Industries, Ltd. | Pyrazole compounds |
CA2515119A1 (en) | 2003-02-07 | 2004-08-19 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivative |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
ES2275218T3 (es) | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
ATE384264T1 (de) | 2003-05-20 | 2008-02-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe mit kinasehemmender wirkung |
PL1635824T3 (pl) * | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
AU2004259662B2 (en) | 2003-06-26 | 2008-08-07 | Mereo Biopharma 1 Limited | 5-membered heterocycle-based p38 kinase inhibitors |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
EP1687284B1 (en) | 2003-07-25 | 2008-10-29 | Novartis AG | p-38 KINASE INHIBITORS |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
WO2006116355A1 (en) * | 2005-04-22 | 2006-11-02 | Kalypsys, Inc. | Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
US20070054884A1 (en) * | 2005-08-31 | 2007-03-08 | Emergent Product Development Gaithersburg Inc. | 4-substituted 2-aryloxyphenol derivatives as antibacterial agents |
AU2006307657B2 (en) * | 2005-10-28 | 2010-10-28 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
KR20080090449A (ko) * | 2005-12-23 | 2008-10-08 | 아스트라제네카 아베 | Gerd 및 ibs의 치료를 위한 피라졸 |
AU2007223342A1 (en) * | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
JP2007205153A (ja) * | 2006-08-07 | 2007-08-16 | Seiki Hanbai Co Ltd | 網戸用ネットの押さえ部材 |
US8128460B2 (en) * | 2006-09-14 | 2012-03-06 | The Material Works, Ltd. | Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell |
CN101616667A (zh) * | 2006-10-27 | 2009-12-30 | 百时美施贵宝公司 | 可用作激酶抑制剂的杂环酰胺化合物 |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
JP5568312B2 (ja) * | 2007-02-13 | 2014-08-06 | アーべー・シオンス | キナーゼ阻害剤としての2−アミノチアゾール化合物の合成方法 |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
WO2008127975A2 (en) * | 2007-04-11 | 2008-10-23 | Alcon Research, Ltd. | Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
KR20240045364A (ko) | 2007-08-29 | 2024-04-05 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
CL2009000851A1 (es) * | 2008-04-08 | 2009-07-17 | Gruenenthal Gmbh | Compuestos derivados de sulfonamida; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento de dolores agudos, viscerales, neuropaticos o cronicos provocados por inflamacion, migraña, diabetes, problemas respiratorios, entre otros. |
WO2009155388A1 (en) | 2008-06-20 | 2009-12-23 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
EP2307411B1 (en) * | 2008-06-20 | 2014-01-01 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as kinase inhibitors |
KR20110070885A (ko) * | 2008-10-23 | 2011-06-24 | 론자 리미티드 | 치환된 피라졸의 합성 방법 |
JP5721722B2 (ja) * | 2009-10-01 | 2015-05-20 | アルコン リサーチ, リミテッド | オロパタジン組成物およびその使用 |
EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
BR112012018358A2 (pt) | 2009-12-21 | 2016-08-09 | Bayer Cropscience Ag | tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos |
AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
JP6042896B2 (ja) | 2011-10-06 | 2016-12-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としての複素環ピリ(ミ)ジニルピラゾール |
US9314026B2 (en) | 2011-10-06 | 2016-04-19 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
CN103360315B (zh) * | 2013-07-22 | 2015-03-04 | 山东大学 | 一种芳杂氧乙酰肼类衍生物及其制备方法与应用 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1261124B (de) * | 1961-09-22 | 1968-02-15 | Hoechst Ag | Verfahren zur Herstellung von Pyrazolen |
GB1245283A (en) * | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
US3984431A (en) * | 1972-03-15 | 1976-10-05 | Claude Gueremy | Derivatives of pyrazole-5-acetic acid |
FR2509729A1 (fr) * | 1981-07-15 | 1983-01-21 | Pharmindustrie | Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole |
US5051518A (en) * | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
JP2753659B2 (ja) * | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
JPH04145081A (ja) * | 1990-10-06 | 1992-05-19 | Kumiai Chem Ind Co Ltd | ピラゾールカルボン酸誘導体及び除草剤 |
WO1992019615A2 (en) * | 1991-04-24 | 1992-11-12 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
GB9204958D0 (en) * | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
DE4328228A1 (de) * | 1993-08-23 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von Pyrazol und dessen Derivaten |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
JPH0899975A (ja) * | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | 5員複素環置換テトラゾリノン誘導体および除草剤 |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
JPH11508267A (ja) * | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
GB2361824B (en) * | 2000-04-27 | 2004-05-26 | Roke Manor Research | Improvements in or relating to electronic timing systems |
-
1998
- 1998-05-22 IL IL13273698A patent/IL132736A0/xx unknown
- 1998-05-22 AR ARP980102380A patent/AR037061A1/es unknown
- 1998-05-22 KR KR1019997010771A patent/KR20010012808A/ko not_active Application Discontinuation
- 1998-05-22 EP EP98924924A patent/EP0983260A2/en not_active Withdrawn
- 1998-05-22 CN CN98807326A patent/CN1264376A/zh active Pending
- 1998-05-22 BR BR9809451-3A patent/BR9809451A/pt not_active Application Discontinuation
- 1998-05-22 RU RU99126510/04A patent/RU2249591C2/ru not_active IP Right Cessation
- 1998-05-22 US US09/083,923 patent/US5932576A/en not_active Expired - Fee Related
- 1998-05-22 AU AU76981/98A patent/AU755498B2/en not_active Ceased
- 1998-05-22 WO PCT/US1998/010807 patent/WO1998052937A2/en not_active Application Discontinuation
- 1998-05-22 JP JP55075598A patent/JP2002502379A/ja not_active Abandoned
- 1998-05-22 PL PL98336990A patent/PL336990A1/xx unknown
- 1998-05-22 CA CA002288741A patent/CA2288741A1/en not_active Abandoned
-
1999
- 1999-11-17 NO NO995635A patent/NO995635L/no unknown
Also Published As
Publication number | Publication date |
---|---|
PL336990A1 (en) | 2000-07-31 |
NO995635D0 (no) | 1999-11-17 |
RU2249591C2 (ru) | 2005-04-10 |
IL132736A0 (en) | 2001-03-19 |
AU7698198A (en) | 1998-12-11 |
US5932576A (en) | 1999-08-03 |
JP2002502379A (ja) | 2002-01-22 |
CA2288741A1 (en) | 1998-11-26 |
EP0983260A2 (en) | 2000-03-08 |
AU755498B2 (en) | 2002-12-12 |
CN1264376A (zh) | 2000-08-23 |
NO995635L (no) | 1999-11-17 |
BR9809451A (pt) | 2000-06-20 |
WO1998052937A3 (en) | 1999-03-11 |
WO1998052937A2 (en) | 1998-11-26 |
KR20010012808A (ko) | 2001-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037061A1 (es) | Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos | |
AR035836A1 (es) | Pirazoles sustituidos como inhibidores de la p38 quinasa, proceso para la preparacion de dichos inhibidores, composiciones farmaceuticas de dichos inhibidores y uso de los mismos | |
AR040336A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto | |
HUP9902455A2 (hu) | 6-Fenil-piridil-2-amin-származékok, ezeket tartalmazó gyógyászati készítmények | |
AP1468A (en) | Hiv inhibiting pyrimidine derivatives. | |
HU9300251D0 (en) | Purified tetrahydro-pyrimidine derivatives and pharmaceutical preparatives containing them | |
NO20052378L (no) | Pre-organiserte trisykliske integraseinhibitorforbindelser | |
AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
PT77308B (en) | Antibacterial agents | |
CA2673254A1 (en) | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections | |
AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
AR070994A1 (es) | Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridina, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales | |
CA2072785A1 (en) | Pharmacologically active hydrazine derivatives and processes for the preparation thereof | |
AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
ES488657A1 (es) | Procedimiento para la preparacion de derivados de aminopro- panol | |
AR045694A1 (es) | Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion | |
PH12018500294A1 (en) | 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
EP0613477A1 (en) | Triazine derivatives for enhancing antitumor activity | |
AR045006A1 (es) | Derivados de quinazolinona 5-sustituidos | |
AR032158A1 (es) | Compuestos para tratar el desacomodamiento fundico, composiciones farmaceuticas que los comprenden, proceso para preparar dichas composiciones y proceso para preparar tales compuestos | |
ECSP034619A (es) | Derivados de pirimidina | |
AR012097A1 (es) | UN COMPUESTO DERIVADO DE 2,3-DIHIDROFURO[3,2-B]PIRIDINA, UN PROCEDIMIENTO DE PREPARACIoN DE DICHO COMPUESTO Y UN MEDICAMENTO Y UNA COMPOSICONFARMACEUTICA QUE LO COMPRENDEN. | |
MY124696A (en) | Pde iv inhibiting pyridine derivatives. | |
NO306675B1 (no) | Pyridazinon-derivater, bronkodilatator, anti-allergisk medikament og anti-blodplatemiddel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |